Press release
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board. Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study. Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an Associate Professor working as a Specialist Registrar at the Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany. Prof. Dr. Grimmer is head of the Centre for Cognitive Disorders, which specializes in early and differential diagnosis of patients with cognitive impairment. The main focus of Prof. Dr. Grimmer’s research is assessing the usefulness of biomarkers in predicting neurocognitive disorders. He has authored numerous peer reviewed articles, amongst others the first studies that assessed the utility of amyloid PET for differential diagnosis of neurodegenerative diseases and to track Alzheimer’s disease progression. In addition, he has served as a national coordinating investigator and as a principal investigator in more than 70 drug trials including all monoclonal antibodies against cerebral amyloid load. “I’m excited to join Anavex’s Scientific Advisory Board at this time of important growth and evolution of the Company,” said Professor Dr. Grimmer. “There is such a significant unmet medical need around the globe caused by Alzheimer’s disease and patients in the Phase 2b/3 ANAVEX®2-73-AD-004 study performed better even after a year despite the progression of this devastating disease. It would be groundbreaking for patients and their loved ones if healthcare professionals are able to provide a therapeutic which can be taken orally and is generally safe, which the study indicates, ANAVEX®2-73 (blarcamesine) is a likely candidate.” “We are pleased to welcome Professor Timo Grimmer to Anavex’s Scientific Advisory Board,” stated Christopher U Missling, PhD, President and Chief Executive O...